Jiangsu Yuyue Science & Technology Development

Jiangsu Yuyue Science & Technology Development

Wu Guangming founded Jiangsu Yuyue Science & Technology Development as the investment vehicle attached to Yuwell Medical, a Shenzhen-listed home-care and clinical-device manufacturer with roots in Danyang, Jiangsu. The family wealth originates from Yuwell Medical, which Wu built over decades into one of China's dominant domestic players in respiratory care, blood-pressure monitoring, and oxygen therapy. His son Wu Qun now serves as CEO of the operating company, while the Yuyue entity pursues strategic investments that extend the healthcare footprint beyond in-house manufacturing. The firm's deployment spans direct equity in listed Chinese healthcare companies, cross-border acquisitions of medical-technology assets, and early-stage venture deals in medtech. Its most visible moves are strategic rather than purely financial: it held a significant position in Wandong Medical, a Beijing-based imaging-equipment maker, which was sold to Midea Group in 2021 (per public record). It also partnered with Jack Ma-backed Yunfeng Capital to acquire Italian ultrasound and MRI specialist Esaote, signaling an appetite for importing advanced diagnostic technology into China's hospital supply chain. Another disclosed holding is a stake in Yunnan Baiyao, the iconic Chinese traditional-medicine and wound-care conglomerate, a deal that placed Yuyue alongside fellow strategic investor New Huadu Industrial Group. Scale figures are not publicly disclosed. The firm's known assets include an industrial headquarters campus in Danyang, a commercial center in Shanghai, and a Gulfstream G550. The operating company Yuwell Medical employs thousands and reported revenues exceeding RMB 6 billion in recent years, providing a capital base that makes Yuyue's investment capacity material by Chinese corporate-venture standards. An associated Yuwell Foundation directs philanthropic giving, though its separation from investment activities is not detailed in public filings. Yuyue's structural differentiator is its role as a strategic acquirer inside China's state-dominated hospital-supply ecosystem. Rather than a pure family office, it functions as a listed-corporate extension with a mandate to consolidate domestic device makers and selectively import foreign technology. Its 2021 exit from Wandong Medical—selling to Midea, an appliance giant entering healthcare—illustrates a willingness to rotate out of positions when a larger industrial logic presents itself.